Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Robafen Cough Formula Expectorant (guaifenesin USP 200 mg in each 10 mL) Recalled by Torrent Pharma Inc Due to cGMP Deviations: Potential product contamination with Burkholderia cepacia...

Date: May 21, 2019
Company: Torrent Pharma Inc
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Torrent Pharma Inc directly.

Affected Products

Robafen Cough Formula Expectorant (guaifenesin USP 200 mg in each 10 mL), a) 4 Fl. oz. (118 mL) bottle, NDC: 0904-0061-00, b) One Pint ( 473 mL) bottle, NDC: 0904-0061-16, Distributed by Major Pharmaceuticals, Livonia MI 48152.

Quantity: 984,888 bottles

Why Was This Recalled?

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Where Was This Sold?

Product was distributed to 9 distributors, direct accounts and relabelers who may have further distributed the product throughout the United States.

About Torrent Pharma Inc

Torrent Pharma Inc has 44 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report